Maximus vs Eden Health: Price, care, and program differences

Maximus vs Eden Health boils down to pricing model, medication sourcing, and care scope. Early verdict: Maximus emphasizes a low flat direct-pay compounded semaglutide program at $132.99 per month with telemedicine prescribing and U.S. pharmacy fulfillment, while Eden Health advertises lower monthly pricing for semaglutide at $99 and a lifetime price guarantee plus guided care.

See Maximus pricing and telemedicine program

Direct comparison summary: cost, product type, and care

Both providers offer online clinician review and ship medication. Major differences supported in the source are: price and price guarantees, compounded versus unspecified product sourcing, program level of guidance, and availability details and regulatory notes. These differences determine who each service is best for.

Criteria	Maximus	Eden Health
Starting price	$132.99 per month (direct-pay)	$99 per month for semaglutide
Medication type	Compounded semaglutide filled through U.S. pharmacies	Semaglutide and tirzepatide offered; product approval status must be confirmed
Program model	Direct-pay telemedicine, prescriptions approved by licensed doctors	Guided GLP-1 program with clinician review and support
Price guarantee	No lifetime guarantee stated	Lifetime price guarantee stated
Shipping and fees	Free priority or expedited shipping stated	Free expedited shipping stated; no membership fees
Regulatory note	Compounded medications are not FDA-approved	Medication-specific approval status must be confirmed; branded and compounded products are not interchangeable

Pricing and billing: predictability vs lower list price

Maximus positions itself as a low flat-rate direct-pay option at $132.99 per month with no insurance billing. The source repeatedly notes a low flat rate and transparent direct-pay pricing. Eden Health advertises monthly pricing at every dose with semaglutide at $99 and tirzepatide at $129, and a lifetime price guarantee. The evidence does not supply insurance billing details beyond “no insurance required” for Eden, nor details on billing mechanics for renewals beyond the lifetime price guarantee claim.

View Eden Health guided program and pricing

Medication sourcing and regulatory notes

Maximus explicitly uses compounded semaglutide filled through trusted U.S. pharmacies and the source includes the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Eden Health lists semaglutide and tirzepatide pricing and states that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Use of compounded medication and approval status are distinct facts present in each provider record.

If FDA approval or branded products matter to you, the sources require confirming product type and approval status with each provider before enrolling.

Care model and program support

Maximus emphasizes convenient telemedicine access, prescriptions approved by licensed doctors, and filling through U.S. pharmacies. The offering is described as a straightforward, direct-pay model without in-person visits. Eden Health positions itself as a guided GLP-1 program that combines medication, care, and support under one monthly price and highlights clinician-reviewed programs. The captured Eden content emphasizes a guided program and clinician review but does not supply granular details on the nature or frequency of coaching or support interactions.

Check Maximus telemedicine and prescription process

Availability, limits, and notable program details

The Maximus source states availability in all 50 states except Mississippi and notes eligibility accommodations for prior GLP-1 usage subject to dosing rules for certain starter packs. Eden Health source cautions that pricing, eligibility, pharmacy, state coverage and renewal terms may change and recommends confirming eligibility, medication, total cost, renewal terms and state availability before enrollment. Specific state lists for Eden were not supplied in the captured evidence.

Regulatory and outcome claims

Maximus materials include outcome-related study citations and asserts participant average results in captured marketing copy; treat those as provider statements. The regulatory note for compounded medications appears in both provider records as a point to confirm product status. The Eden source states that treatment is available only when a licensed clinician determines it is medically appropriate.

Confirm Eden Health eligibility and program details

Final comparison and how to choose

Maximus vs Eden Health is a choice between a simple, low flat-rate compounded semaglutide direct-pay plan and a lower advertised monthly price with a lifetime price guarantee combined with a guided program. Maximus: compounded semaglutide, telemedicine prescribing, U.S. pharmacy fulfillment, $132.99 per month and availability in most states. Eden Health: semaglutide at $99 per month, tirzepatide at $129 per month, lifetime price guarantee, and a guided clinician-reviewed program.

Choose Maximus if you want a straightforward direct-pay compounded semaglutide option prescribed via telemedicine and filled through U.S. pharmacies at a low flat rate and if you are comfortable with compounded medication and Maximus’s stated state availability.

Choose Eden Health if you prioritize a lower listed monthly price for semaglutide, a lifetime price guarantee, and an advertised guided GLP-1 program with clinician review, provided you confirm eligibility, product type, pharmacy sourcing, renewal terms and state availability before enrolling.